1,2,2,3,4,4,5,6,6,8,8,9,9,10-Tetradecafluoro-7,10-dimethyladamantane

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,2,2,3,4,4,5,6,6,8,8,9,9,10-Tetradecafluoro-7,10-dimethyladamantane
• 化学式: C₁₂H₆F₁₄
• 分子量: 416.15
• InChiKey: LRSXUIVRJXEVBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  14

文献信息

• [EN] TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME<br/>[FR] COMPOSÉS DE DÉRIVÉS DE TRÉPROSTINIL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CORSAIR PHARMA INC

  公开号：WO2016010538A1

  公开（公告）日：2016-01-21

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  由I、II、III和IV式代表的化合物包括曲前列素和前列环素类似物的前药。用途包括治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量调整以适应特定的应用。可以使用经皮应用。
• [EN] PRODRUGS OF TREPROSTINIL<br/>[FR] PROMÉDICAMENTS DE TRÉPROSTINIL
  申请人：THERATROPHIX LLC

  公开号：WO2014110491A1

  公开（公告）日：2014-07-17

  Prodrugs of treprostinil are provided which can be used in the treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  Treprostinil的前药提供了，可用于治疗肺动脉高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定应用。可以使用经皮应用。
• [EN] PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY<br/>[FR] PARTICULES DE PHOTOSENSIBILISATEUR DESTINÉES À L'IMAGERIE MÉDICALE ET/OU À LA THÉRAPIE PHOTODYNAMIQUE
  申请人：DCB USA LLC

  公开号：WO2014189796A1

  公开（公告）日：2014-11-27

  Photosensitizer particle contrast agents are suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. The core has an echogenic contrast-enhancing material loaded therein. The photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Methods for medical imaging use imaging compositions containing the photosensitizer particle contrast agents.

  光敏剂颗粒对比剂适用于医学成像和/或光动力疗法。光敏剂颗粒对比剂具有一个被壳包裹的壳和核心。壳主要由多个光敏剂结合物组成。每个光敏剂结合物由光敏剂和至少一个与光敏剂共价结合的可生物降解聚合物组成。核心中装载有增强超声对比的材料。多个光敏剂结合物中至少一个的光敏剂具有磁性增强对比剂，例如，螯合到其中的顺磁离子。用于医学成像的方法使用含有光敏剂颗粒对比剂的成像组合物。
• [EN] PERFLUOROCARBON-SOLUBLE COMPOUNDS<br/>[FR] COMPOSÉS SOLUBLES DANS DES PERFLUOROCARBONES
  申请人：UNIV SOUTHERN CALIFORNIA

  公开号：WO2005107764A1

  公开（公告）日：2005-11-17

  The invention describes syntheses and purifications of several perfluorocarbon-soluble compounds having a general formula RF - L - X or RF - L - X - L - RF, wherein RF is a perfluorocarbon group, X is a hydrophilic moiety, and L is an amide linkage of general structure -CO-NH-. The invention also provides microemulsions comprising a PFC forming an oil phase, water or aqueous solution forming a water phase, and a PEG-based fluorosurfactant with an HFB (hydrophilic groups to fluorophilic groups balance) value from about 7 to about 13. The invention also provides a method of amidification of a fluorocompound. The method involves mixing perfluoracid chloride of a general formula CnF2n+1COCI with a compound containing an amine group with a general structure R-NH2 under reaction conditions sufficient to obtain a product having a general formula CnF2n+1-CONH-R.

  该发明描述了合成和纯化几种可溶于全氟碳化合物的化合物，其通用式为RF - L - X或RF - L - X - L - RF，其中RF是全氟碳基，X是亲水基团，L是一般结构为-CO-NH-的酰胺键。该发明还提供了微乳液，包括形成油相的PFC，形成水相的水或水溶液，以及具有HFB（亲水基团到亲氟基团平衡）值约为7至13的基于PEG的氟表面活性剂。该发明还提供了一种氟化合物的酰胺化方法。该方法涉及将通用式为CnF2n + 1COCI的全氟酸氯与含有一般结构为R-NH2的胺基团的化合物在足够的反应条件下混合，以获得通用式为CnF2n + 1-CONH-R的产物。
• TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME
  申请人：Corsair Pharma, Inc.

  公开号：US20150166503A1

  公开（公告）日：2015-06-18

  Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

  式子 I、II、III 和 IV 所代表的化合物包括替前列环素和前列环素类似物的前药。用途包括治疗肺高压（PH）或肺动脉高压（PAH）。这些化合物的结构可以根据适当的治疗剂量适应特定的应用。可以使用经皮应用。